NEPH vs NSRX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NEPH presents a contradictory profile with a stable Piotroski F-Score of 4/9 and a very strong balance sheet, yet it is fundamentally overvalued. The current price of $2.88 significantly exceeds both the Graham Number ($1.54) and the Intrinsic Value ($0.77), suggesting a speculative premium. While revenue growth remains positive at 22.2%, the catastrophic collapse in earnings growth (-82.40% YoY) and a bearish technical trend (0/100) outweigh the analyst target of $7.00.
NSRX exhibits significant financial fragility, highlighted by a weak Piotroski F-Score of 3/9 and a devastating ROA of -107.15%. The company is currently pre-revenue or lacks reported earnings, resulting in a high Price-to-Book ratio of 8.79 that is unsupported by fundamental profitability. While liquidity remains stable with a current ratio of 2.25, the technical trend is overwhelmingly bearish with a 67.3% decline over the past year. There is a massive disconnect between the current market price of $2.70 and the speculative analyst target of $20.00.
Compare Another Pair
Related Comparisons
NEPH vs NSRX: Head-to-Head Comparison
This page compares Nephros, Inc. (NEPH) and Nasus Pharma Ltd. (NSRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.